Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate and Rinvoq
Determining the interaction of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate and Rinvoq and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Professional:MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MANAGEMENT: Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Generic Name: cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Brand name: Symtuza
Synonyms: Cobicistat, darunavir, emtricitabine, and tenofovir, Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Riociguat
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Riomet
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Riomet Oral Suspension
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Risankizumab
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Risankizumab-rzaa topical
- Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Fumarate-Risedronate
- Rinvoq-Darvocet
- Rinvoq-Darvocet A500
- Rinvoq-Darvocet-N
- Rinvoq-Darvon
- Rinvoq-Darzalex
- Rinvoq-Dasabuvir, ombitasvir, paritaprevir, and ritonavir